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Germany is considered to be a low prevalence country for viral Hepatitis B, C and D (HBV,
HCV, HDV). However, the burden of disease can be high among subpopulations. To meet
the world Health Organization (WHO) viral hepatitis (VH) elimination goals, a national strat-
egy was developed by the German government in 2016. We performed a scoping review to
understand the baseline epidemiological situation in Germany regarding burden of disease,
sequelae and care of HBV, HCV and HDV as a reference to monitor the progress of the
national VH elimination and to identify further knowledge gaps and research needs.
Methods
The protocol of the systematic review was prepared following the PRISMA statement
guidelines for scoping reviews. Relevant search terms were used to identify eligible studies
according to the research questions. We searched six online databases for original work
published between January 2005 and March 2017. Based on the identified references, a
matrix was developed presenting the eligible literature by targeted population group and
outcome category.
Results
104 publications were eligible for extraction covering 299 outcome results. The population
groups targeted in the identified studies included the general population and proxy popula-
tions, a range of clinical populations, people who inject drugs, men who have sex with men,
healthcare workers, people in prisons and different migrant/mobile populations. Other vul-
nerable populations (e.g. sex workers) were not targeted. Overall, good evidence was found
for HBV and HCV prevalence and HBV vaccination coverage in the GP and proxy popula-
tions. Evidence for these outcomes was weaker in populations at risk for VH. For HBV and
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HCV incidence and mortality, we identified large evidence gaps in all population groups.
Outcomes on VH sequelae and care were mainly covered by studies in clinical populations
of people living with viral hepatitis. For HDV the overall evidence available was scarce.
Conclusions
We created a comprehensive evidence-based overview on the current epidemiological situ-
ation of viral hepatitis in Germany. We identified knowledge gaps for further research and
established a baseline for future monitoring of viral hepatitis elimination goals in Germany.
Background
Globally, viral hepatitis (VH) is a leading cause of morbidity and mortality. An estimated 257
and 71 million people are chronically infected with Hepatitis B (HBV) and Hepatitis C (HCV),
respectively. Fifteen to twenty million (5.0% of those with HBV) are infected with Hepatitis D
virus (HDV) [1]. In the World Health Organization (WHO) European Region, an estimated
15 and 14 million people are suffering from chronic HBV and HCV infection, respectively [2].
The major transmission routes of HBV, HCV and HDV are the exposure to infected blood,
such as through unsafe injection practices, via sexual contact and transmission from mother to
child during birth. As a result, some populations are more vulnerable to VH than others (here-
after populations at risk for VH) [3]. Chronic infections can cause liver cirrhosis and liver can-
cer and liver transplantation may be the ultima ratio for individuals with acute or chronic liver
failure due to VH. According to estimates by the WHO, VH caused 1.34 million deaths glob-
ally in 2015 [4]. The more rare HDV leads to a more severe infection and the rapid progression
to adverse outcomes.
In recent years, highly effective direct-acting antiviral treatment options for HCV infection
have become available and this new treatment as well as the efficient HBV vaccine, available
since 1982 in Germany, have made the elimination of VH a feasible target. In 2016, the first
Global Health Sector Strategy on VH 2016–2021 (GHSS) [5] was endorsed by the World Health
Assembly. It offers a strategy to work towards the elimination of VH as a major public health
threat by 2030. In the same year, the Action Plan for the Health Sector Response to VH in the
World Health Organization (WHO) European Region was developed and approved by the
WHO Regional Committee [2].
Germany is considered a low-prevalence country for HBV and HCV, which was demon-
strated in the last national population-based studies in adults and children (DEGS1, 2008–
2011 and KiGGS Wave 1, 2009–2012) [6, 7]. However, the actual prevalence may be higher, as
vulnerable populations at higher risk of VH infection are often less represented in population-
based studies [8, 9].
In 2016, an integrated national strategy for HIV, HBV and HCV and other sexually trans-
mitted diseases was approved by the German Government to improve the responses to these
diseases [10]. Core points of this strategy are the extension of integrated prevention, testing
and care services for reducing transmission, increasing early diagnosis and improving care
with a focus on the further expansion of demand-orientated services for populations at risk
for VH and with a high burden of VH and combatting stigma related to HIV, viral hepatitis
and STI. To plan and implement new services as well as to control the success of the national
strategy, differentiated knowledge about the epidemiological situation of HBV, HCV and
HDV including data on burden of disease, sequelae and prevention/care in the general
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population (GP, refers to the national population) and populations at risk for VH in Germany
is essential. Up to now, there has been no systematic overview of the existing scientific evi-
dence regarding VH, which could serve as a reference for monitoring the progress of VH elim-
ination. Therefore, we conducted a scoping review to provide an extensive baseline overview
of the available evidence until 2017 regarding the extent, variety and nature of published litera-
ture in this area. Moreover, the aim of our study was to identify research gaps in order to sup-
port the planning of future research in the light of the hepatitis elimination goals [1].
Methods
Research question
Based on the aim of the scoping review, we formulated 13 specific research questions to iden-
tify relevant published literature covering several aspects of VH epidemiology in the GP and
populations at risk for HBV, HCV and HDV in Germany:
1. What is the prevalence of HBV, HCV and HDV in Germany?
2. What is the incidence of HBV, HCV and HDV in Germany?
3. What is the mortality of HBV, HCV and HDV in Germany?
4. What are the genotypes of HBV, HCV and HDV?
5. What are the routes of transmission for HBV, HCV and HDV in Germany?
6. What is the proportion of HBV, HCV and HDV co-infections in Germany?
7. What is the burden of liver cirrhosis due to HBV, HCV and HDV in Germany?
8. What is the burden of hepatocellular carcinoma due to HBV, HCV and HDV in Germany?
9. What is the quality of life of people living with HBV, HCV and HDV?
10. What proportion of the population is diagnosed with HBV, HCV and HDV in Germany?
11. What proportion of the population is treated for HBV, HCV and HDV in Germany?
12. What is the proportion of liver transplantation due to HBV, HCV and HDV in Germany?
13. What is the HBV immunisation coverage in Germany?
HBV, HCV and HDV infection and HBV immunisation were defined as stated in the corre-
sponding publications. This included infection/immunity confirmed by a serological test, self-
reported or extracted from medical records. Liver cirrhosis, hepatocellular carcinoma and
acute liver failure were defined as stated in the corresponding publication and included confir-
mation by clinical/serological tests, self- report or extraction from medical records. The pro-
portion of HBV, HCV and HDV diagnosed individuals was defined as the proportion of
positive tested individuals (as defined in the corresponding publication) not knowing resp.
already knowing their infection status. The proportion of HBV, HCV and HDV treated indi-
viduals included intended, ongoing, finished and interrupted treatment as defined in the cor-
responding publication. The HBV immunisation coverage included complete and incomplete
vaccination against HBV confirmed by a serological test, self-reported or extracted from a
medical records as defined in the corresponding publication. Only descriptive epidemiology
was considered, while analytical epidemiology (e.g. risk factors associated with outcomes in
the research questions) was outside the scope of this review.
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Systematic literature search
The research and reporting methods of the scoping review were consistent with the preferred
reporting items for systematic reviews and meta-analysis extension for scoping reviews (PRIS-
MA-ScR) ([11], S1 Table) and partly with the Cochrane Collaboration (https://training.
cochrane.org/handbook). An a priori protocol adapted from the protocol template of the Inter-
national prospective register of systematic reviews (PROSPERO) [12] was prepared and will be
provided on request from the corresponding author.
The literature search was conducted in six electronic databases (MEDLINE, EMBASE,
Europe PMC, Scopus, Bielefeld Academic Search Engine (BASE) [13] and CC Med ([14], a
database specialised in German medical journals). To develop a comprehensive search cover-
ing all eligible literature containing data on the epidemiology of HBV, HCV and HDV in Ger-
many the 13 research questions were translated into a table of Populations and Outcomes,
adapted from the PICO criteria (Participants, Interventions, Comparator, Outcome [15]).
Based on the table of outcomes three search strings were defined, one for each of the three
viruses. The string also included appropriate regional terms limiting the search to data from
Germany. The final search strings were checked for correctness by all team members. The
search is attached as additional file (S1 Text). Before conducting the final search, internal and
external experts indexed published journal articles relevant for each research question. To
verify the search string, we screened if the index articles were represented in a test run of the
search. The strings were run in the six electronic databases adapted to the format required for
each database including medical subject headings for the search in PubMed (MeSH Terms)
and EMBASE (EMTREE). The final search was conducted on 9th March 2017 (cut-off date)
and was restricted to references published between 1st January 2005 to 9th March 2017 in
English or German language. The references that were retrieved through the online search
were imported to Endnote and duplicates were removed. Additional relevant references were
subsequently identified manually from the reference lists of the publications eligible forfull-
text-screening. Moreover, reports of national surveillance data that are not published in the
six electronic databases, were included in the review.
Study selection criteria
We developed specific inclusion criteria to identify eligible publications. Included in the review
were i) original works (analyses of data from observational studies (e.g. cross-sectional studies,
cohort studies, case-control studies, case series from the national surveillance, of secondary or
registry data and of reviews with a systematic approach), ii) Full-text-publications as peer-
reviewed/non-peer-reviewed journal articles and other forms of publications (e.g. doctoral
theses), iii) with end of data collection after 1st January 205 and publication between 1st Janu-
ary 2005 and 9th March 2017 and iiii) published in German or English language. From cohort
studies, only cross-sectional outcomes were considered and from case-control studies only
data gained from cases. Publications without full text (e.g. conference abstracts) were excluded.
Furthermore, publications that did not report basic demographics (e.g., age, sex) of partici-
pants or with major errors in reporting (e.g. error in numbers, wrong calculations) were
excluded. If multiple publications reported identical outcomes from the same study or cohort
without new aspects relevant for the research questions, the newer publication was excluded.
For the specific study selection criteria see S1 Fig.
Study selection process
All publications were screened for relevance applying the study selection criteria The screening
was conducted by two independent reviewers working in parallel, first for title and abstract
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followed by the full text. After the screening of 50 references, a validation of the screening pro-
cess was conducted by comparing the screening results and discussing them within the team.
Throughout the screening process, discrepancies were discussed and a third reviewer was con-
sulted if consensus was not reached. The reasons for exclusion were documented only for full
text publications (Fig 1), and track of the excluded studies was kept in a separate table (avail-
able upon request).
Data extraction
Three main outcome categories (15 sub-categories) were derived from the research questions
(outcome categories, Fig 2) to perform the extraction of the relevant data on outcome level. A
standardised extraction sheet (Microsoft Excel) was developed containing 114 variables on
outcome identifier, name and year of publication, author, study aim, study design (study pop-
ulation, study region, data collection period, sample, recruitment and data collection),
Fig 1. Flow chart of the study selection.
https://doi.org/10.1371/journal.pone.0229166.g001
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outcome category and outcome results. After piloting the extraction sheet within the review
team, relevant outcomes from eligible publications were extracted by one reviewer and cross-
checked by a second one. Discrepancies between the reviewers were solved as described in the
study selection process. The results were compiled in the extraction sheets. All extracted infor-
mation was transferred to the sheet as stated in the corresponding publication. Minor errors in
reporting/analysis (e.g. minor calculation errors) were discussed between the reviewers and
corrected. For some publications more than one outcome was extracted. For each publication,
the design of the corresponding study was determined. When more than one study design was
used for different outcomes, the design with the highest evidence was reported.
Data analysis
The identified literature was analysed for the extent of evidence, measured by the number of
publications. Moreover sample size, place of data collection, study design, data collection tools,
outcome category and population group were assessed on outcome and publication level. For
this, the extraction sheets were subsequently collected and converted into a spreadsheet table
by outcome. Relevant population groups were identified based on the WHO guidelines on
Hepatitis B and C testing [3] and adapted to the German context. They included: i) the GP, ii)
sub-populations which may represent a large proportion of the national population and there-
fore act as a proxy for the GP (blood donors, pregnant women and individuals born between
1946 and 1964, called baby boomers), iii) clinical populations (populations with non-VH
related underlying disease and people with VH in hepatological care (PLWVH)), iiii) popula-
tions at risk for VH due to risk behaviour/exposure (household contacts of PLWVH, health-
care workers (HCW), people living with HIV (PLWH), men who have sex with men (MSM),
people in prison and closed settings, people who inject drugs (PWID), sex workers) or because
Fig 2. Outcome categories and sub-categories for the matrices.
https://doi.org/10.1371/journal.pone.0229166.g002
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they are part of a population with high VH seroprevalence, e.g. mobile or migrant populations
from intermediate- and high-endemic countries. The study population of each outcome was
assigned to a population group according to the definition used in the corresponding publica-
tion. When no definition was available, the review team discussed and allocated the outcomes
of the publications. In general, only one population group was assigned per outcome, but
exceptionally studies with outcomes in HIV positive MSM [16–20] were allocated to both
population groups.
The outcomes from the spreadsheet table were classified in an evidence map by outcome
category (Fig 2) and population group separately for HBV, HCV and HDV. In order to facili-
tate the readability, the outcomes in one cell were summarised on publication level (with num-
ber of outcomes still disclosed). Some references were assigned to more than one cell because
they covered outcomes in different outcome categories/population groups. The evidence map
contained information on place of data collection (local = one city/regional = more than one
city in one region/nationwide = more than one city all over the country), size of study sample
and quality grading on outcome level (see below).
The number of identified publications by outcome/population groups is not always corre-
sponding to the number of studies conducted, as some outcomes of studies were split to more
than one publication. In this work, we always referred to the number of outcomes and the
number of publications, not to the number of studies conducted.
Study quality
We developed a basic quality appraisal approach for of each outcome which included two cri-
teria: national representation of the target population (regional or nationwide data collection)
and adequacy of the study instrument for data collection. For details of the classification see
Table 1. These criteria were selected due to their importance for viral hepatitis in Germany
(i.e. are the results on national level and thereby representative for the national German popu-
lation), and the study instrument to evaluate the potential risk of bias in the collected data. The
total score for each criteria classified the outcomes in lower quality (0 and 1) and higher quality
(2 and 3). Publications containing an outcome assessed with a quality index lower than 50% of
the maximum were highlighted in the corresponding cell of the evidence map.
Results
In total, the literature search in the six electronic databases retrieved 18,410 references for
HBV, HCV and HDV. After removal of duplicates, 10,956 references were screened based
on title and abstract. After removing irrelevant references, 627 full text publications were
reviewed. Of these, 294 were excluded due to formal reasons (duplicates, no full text available,
no original data), 27 due to poor quality of reporting and 187 due to content (data outside the
time frame, not relevant for Germany or not relevant for the study question) and 29 due to
other reasons. Ninety articles were included for data extraction and additional 14 references
Table 1. Items for quality appraisal and classification.
Item for quality appraisal 0 1







biological marker clinical diagnosis/histology medical
record physician reported




participant reported medical record report of
physician
https://doi.org/10.1371/journal.pone.0229166.t001
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were identified by manual search. In total, 104 articles were included for data extraction [6, 7,
16–117]. Fifty-eight publications (83%) answered more than one research question and in
total the 104 publications covered 299 outcomes. The stepwise selection of the included publi-
cations is shown in Fig 1.
Ninety-six (92%) of the publications were peer-reviewed journal articles, one a non-peer-
reviewed article, one a book chapter and seven dissertations. Fifty-three (51%) of all identified
publications were published in German. Eleven (11%) publications were studies with an over-
all study population smaller than 200 individuals and 51 (49%) with a study population larger
than 1,000 individuals. On outcome level, for 60 outcomes (20%) less than 200 individuals
were studied. In 40 publications (38%) the recruitment of the study population was nation-
wide. Seventy publications (67%) described studies with a cross-sectional study design, 27
(26%) with a cohort design, five (5%) contained surveillance data and two (2%) were on case-
control studies. Eleven of the cross-sectional studies used data from the national school entry
examinations and two publications with a cohort design were analyses of health insurance
data. Case series analyses were always part of cohort studies. In 21 publications (20%), the out-
comes on VH infection status, HBV vaccination status and/or VH treatment history were self-
reported. In three publications, no information was available on how demographics of the
study population were collected [38, 66, 107]. For the study characteristics of all included
publications see S2 Table.
Hepatitis B
Overall, 167 outcomes related to HBV were extracted from 83 publications. Six of them (in
two publications) were in PLWH. One covered HBV/HCV co-infections in PLWH.
For the outcomes of 32 publications (39%), the data was collected nationwide, for the out-
comes of 12 (14%) regional and for the outcomes of 38 (46%) locally. For one outcome (<1%)
the regional representation of data colletion was not described. For 29 outcomes (in 16 publi-
cations) less than 200 individuals were observed. For 32 outcomes (in 20 publications) the
outcome was self-reported (excl. four outcomes on knowledge about HBV-status and quality
of life). For four outcomes (in three publications) information on how data was collected
from the study population was not provided. Overall, the quality appraisal graded 8% of the
outcomes (n = 14 in 11 publications) as lower quality (criteria see above).
Eighty HBV-related outcomes (in 47 publications) were classified as belonging to the cate-
gory burden of disease, 25 (19) to the category sequelae and 62 (53) to the category care.
In 33 of all HBV related publications (40%) the study population was recruited from the
GP or a proxy population, such as blood donors (seven publications), pregnant women (three
publications) and baby boomers (one publication). For 12 publications (14%) different clinical
populations were studied and 15 publications (18%) were on outcomes in PLWVH. Regarding
populations at risk, in 14 of the publications (17%) the study population were HCW. Only
three publications (4%) were about HBV outcomes in migrant/mobile populations and PWID
each and one in MSM. One publication was about outcomes in PLWH and one studied HIV-
positive MSM.
Considerable evidence was available for HBV prevalence in the GP and proxy populations,
PLWVH and clinical populations, HCW, migrant/mobile populations and PWID; for HBV
incidence in proxy populations for the GP; for transmission routes in the GP, PLWVH; for
liver cirrhosis in PLWVH; for HCC in PLWVH and clinical populations; for proportion diag-
nosed in the GP; for proportion treated in PLWVH and for vaccination coverage in the GP,
clinical populations, HCW and PWID.
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Rare evidence was available for HBV prevalence and incidence in PLWH and MSM, for
mortality and genotype distribution in PLWVH; for liver cirrhosis in the GP and clinical pop-
ulations; for quality of life in PLWVH; for proportion of diagnosed in clinical populations; for
proportion of treated in the GP and for vaccination coverage in household contacts of
PLWVH, PLWH, MSM and migrant populations.
No evidence was available for HBV prevalence in household contacts of PLWVH; for HBV
incidence in the GP, PLWVH and clinical populations, HCW, people in prison, migrant popu-
lations and PWID; for mortality in the GP and proxy populations, clinical populations and all
populations at risk; for genotype distribution in the GP and proxy populations, clinical popula-
tions and all populations at risk, for transmission routes in proxy populations for the GP, in
clinical populations and all populations at risk, for HIV co-infection in proxy populations for
the GP, household contacts of PLWVH, people in prison and migrant/mobile populations; for
acute live failure in the GP and proxy populations, PLWVH and all populations at risk; for
liver cirrhosis in proxy populations for the GP and all populations at risk, for HCC in the GP
and proxy populations and all populations at risk; for quality of life in all populations except
PLWVH, for proportion diagnosed in proxy populations for the GP, PLWVH and all popula-
tions at risk; for proportion treated in proxy populations for the GP, clinical populations and
all populations at risk; for liver transplantation in the GP and proxy populations, clinical popu-
lations and all populations at risk, and for vaccination coverage in proxy populations for the
GP and people in prison.
The detailed extent of evidence for HBV in Germany is also shown in Tables 2 and 5.
Hepatitis C
In total, 146 outcomes in 60 identified publications were related to HCV. Ten of them (in five
publications) were in PLWH.
For the outcomes of 25 publications (42%) the data collection was nationwide, for the out-
comes of 10 (17%) regional and for the outcomes of 25 (42%) local. Less than 200 individuals
were observed for 28 outcomes (in 14 publications). Overall, the quality appraisal graded 5%
of the outcomes (n = 3 in 3 publications) as lower quality (criteria see above).
Ninety-eight HCV-related outcomes (in 50 publications) were assigned to the outcome cat-
egory burden of disease, 24(19) to sequelae and 24 (19) to care.
Regarding populations, 12 publications (20%) focussed on the GP, added by one publica-
tion on baby boomers and one in pregnant women. In 28 publications (47%) clinical popula-
tions were studied. Publications on HCV-related outcomes in other populations at risk for
VH were rare: five publications on studies in MSM, three in HCW, three in PWID, two in
migrant/mobile populations and one in people in prison were identified. In six publications
more than one population group was studied. For example, Kant et al. investigated the GP and
additionally baby boomers as a sub-population [50]. Lugehetmann et al. studied PLWVH and
the household contacts of PLWVH [55].
Considerable evidence was available for HCV prevalence in the GP (incl. proxy popula-
tions), HCW, PLWH and PWID; for HCV incidence in proxy population for the GP; for geno-
type distribution in PLWVH; for transmission routes in the GP, PLWVH and PLWH; for liver
cirrhosis and HCC in PLWVH and clinical populations; for proportion diagnosed in the GP;
for proportion diagnosed in the GP and for proportion treated in the GP and PLWVH.
Evidence was rare for HCV prevalence in clinical populations, people in prison, MSM and
migrant/mobile populations; for HCV incidence in the GP, PLWH and MSM; for mortality
in PLWVH; for genotype distribution in the GP, PLWH, MSM and PWID; for transmission
routes in clinical populations, PLWH and MSM; for acute liver failure in PLWVH and clinical
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populations; for liver cirrhosis in the GP; for quality of life in PLWVH; for proportion of
treated in clinical populations, PLWH, people in prison, MSM and PWID and for liver trans-
plantation in PLWVH.
No evidence was available for HCV prevalence in pregnant women and household contacts
of PLWVH; for HCV incidence in PLWVH and clinical populations, HCW, people in prison,
migrant/mobile populations and PWID; for mortality in the GP and proxy populations, clinical
populations and all populations at risk; for genotype distribution in proxy populations for the
GP, clinical populations, household contacts of PLWVH, HCW, people in prison and migrant/
mobile populations; for transmission routes in proxy populations for the GP, in household con-
tacts of PLWVH, HCW, people in prison, migrant/mobile populations and PWID; for acute
live failure in the GP and proxy populations and all populations at risk; for liver cirrhosis in
proxy populations for the GP and all populations at risk; for HCC in the GP and proxy popula-
tions and all populations at risk; for quality of life in all populations except PLWVH; for pro-
portion of diagnosed in proxy populations for the GP, PLWVH and clinical populations, and
all populations at risk; for proportion of treated in proxy populations for the GP, household
contacts of PLWVH, HCW and migrant/mobile populations and for liver transplantation in
the GP and proxy populations, clinical populations and all populations at risk.
The extent of the evidence for HCV in Germany is shown in Tables 3 and 5.
Hepatitis D
Seven-teen outcomes in eight publications were identified as HDV-related. One publication
included nationwide data collected. The outcomes were classified as follows: seven (4) in
Table 5. Matrix for publications on HBV/HCV and HCV/HDV co-infections (publications by population and out-
come category). Shown are name_year of publication, sample size, place of data collection (local/regional (R) = one or




General population [110], n = 275, R 1
Baby boomer 0
Blood donors [113], n = 2,853,531, N [111], n = 36,139, N 2
Pregnant women 0
People living with viral
hepatitis
[112], n = 718, R [37],
n = 67, R
2
Clinical populations [32], n = 17, R [41], n = 1535, N [48], n = 10,326, N [51],
n = 1,208, R [57], n = 327, R [58], n = 995, N [67], n = 255,
N [94], n = 24, R
9
Household contacts of People
living with viral hepatitis
0
Health care workers
People living with HIV [91], n = 918, R 91
People in prisons 0
Men who have sex with Men 0
Migrant/mobile populations 0
People who inject drugs [28], n = 1361/516, R, (2) 1
N studies (N outcomes) 12(13) 1(1)
�� outcome assessed with a quality index lower than 50% of the maximum
https://doi.org/10.1371/journal.pone.0229166.t005
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burden of disease, eight (6) in sequelae, and two (1) in care. Coherent to the nature of HDV
infection as a HBV superinfection, all identified publications analysed data collected in HBV
positive clinical populations.
No publication was assessed as of low quality. Considerable evidence was available for
HDV prevalence in PLWVH; rare evidence for mortality in PLWVH; transmission routes in
PLWVH, HCV/HDV co-infections in PLWVH; liver cirrhosis in PLWVH; HCC in PLWVH
and clinical populations; proportion of treated in PLWVH and liver transplantation in
PLWVH. For all other combinations no evidence was available. For details of the evidence
map, see Tables 4 and 5.
VH co-infections
Fourteen publications included 16 outcomes regarding HBV/HCV co-infections and one pub-
lication reported one outcome regarding HCV/HDV co-infection. Considerable evidence was
only available for HBV/HCV co-infections in PLWVH. Rare evidence was available for HBV/
HCV co-infections in the GP and proxy populations, PLWH and PWID. For HCV/HDV co-
infection, rare evidence was available in PLWVH.
For details of the evidence map, see Table 5.
Discussion
The aim of our work was to give an extensive overview of the available evidence regarding the
epidemiological situation of HBV, HCV and HDV in different population groups in Germany.
We conducted a scoping review including a comprehensive literature search in electronic data-
bases. We identified overall good evidence for HBV and HCV prevalence and HBV vaccina-
tion coverage in the GP and proxy populations. Evidence for these outcomes was weaker in
populations at risk for VH. For HBV and HCV incidence and mortality, we identified large
evidence gaps in all population groups. Outcomes on VH sequelae and care were mainly cov-
ered by data derived from case series of clinical populations with severe sequelae, treated in
tertiary referral centres. For HDV the overall evidence available was scarce.
The methods of our scoping review were based on the PRISMA-ScR and the Cochrane
collaboration (where applicable) to ensure the transparency of the process and reliability of
this work. The review covered numerous important epidemiological topics leading to multiple
study questions. Subsequently, we applied a broad search string to ensure that all literature
with relevant outcomes were identified. We did not use search terms regarding study popula-
tions to not miss any relevant populations at risk for VH that we did not consider before.
However, we used search terms and language restriction to narrow the search to articles about
Germany. The restriction of the manual literature search to the screening of references during
full text screening and published data from the Robert Koch Institute may have limited the
completeness of the identified literature. However, we identified all our pre-defined index
papers by the electronic search, which validates the sensitivity of our search strings. Relevant
publications only detected by manual search were mainly articles published in national jour-
nals (e.g. the national surveillance journal) and not cited in electronic databases. To illustrate
the identified body of literature, we defined outcome categories and population groups and,
subsequently, created an evidence map. Limitations of using population groups may be (1) the
challenge of allocating the study populations to the appropriate population group because of
different naming and varying quality of the description of population characteristics in the
corresponding publications and (2) the heterogeneity of the assigned study populations
regarding age, sex and risk of VH infection. We defined proxy populations representing the
GP (baby boomers, blood donors and pregnant women). These population groups still do not
PLOS ONE Viral hepatitis epidemiology scoping review
PLOS ONE | https://doi.org/10.1371/journal.pone.0229166 March 9, 2020 17 / 27
perfectly match with the GP, some populations at risk for VH (e.g. subpopulations of migrant/
mobile people or PWID) may be under- or overrepresented in studies conducted in data com-
ing from antenatal care but also in studies generally conducted in hospitals. In the blood donor
surveillance individuals from high risk groups (e.g. PWID, sex workers) as well as individuals
who are chronically infected with HIV, HBV or HCV and know their infection status are highly
underrepresented as they are excluded from blood donation before screening if they report
these risk factors in the pre-screening questionnaire. Therefore the prevalence of infection
among those can be used only as the lower bound of prevalence in the general population.
Apart from content-related variety of the outcomes and study populations, differences in study
designs, methods and number of individuals observed among the included publications limited
the comparability of evidence within and between different outcome categories and population
groups. To provide a rough overview of the data quality for the evidence map we conducted a
basic quality appraisal, assessing the national representation of the target population and the
study instruments used to collect data regarding study population and outcome. The quality
standard of the included publications according to the parameters assessed was overall good,
though around one quarter of publications were of lower quality. However, we did not conduct
a full critical appraisal according to the recommended criteria for systematic reviews (e.g.
AMSTAR and others) for this broad scoping review and our quality appraisal does not reflect
the overall quality of the studies included in our review. For further detailed analysis of the
identified evidence, a comprehensive quality appraisal is essential to evaluate their risk of bias.
Regarding studies in the GP, data from the large population-based surveys DEGS1 (2008–
2011) and KiGGS (Baseline study 2003–2006) provide solid evidence for adults and children,
respectively, but are not very recent. The next examination study among children and young
adults (KiGGS wave 2) has been carried out from 2014–2017 and a new population-based sur-
vey in adults is planned to be conducted by the RKI from 2020–2022. Studies in proxy popula-
tions included several large studies analysing test results of HBV screening during pregnancy
and the national blood donor surveillance. Other evidence for the GP was mostly derived from
large cross-sectional screening studies in hospital emergency departments or medical practices
[25, 32, 36, 50, 100, 114, 115]. All these populations may represent the GP but it should be
taken into account, that there might be a selection bias as population groups possibly differ in
health care-seeking behaviour. Moreover sociodemographics and behaviour of treated patients
might differ in different hospitals depending on the geographical location. In addition to the
population-based surveys, we identified studies which had used statutory health insurance
data for HCV analyses [98, 99]. This data covers 85% of the population, corresponding to the
proportion of persons with statutory health insurance in Germany. This data may still be
biased as some population groups in Germany do not have sufficient access to the German
health system (due to legal or stigma-related barriers) and therefore may be underrepresented
in health insurance based data. Analyses of data from the mandatory national school entry
health examination provided valuable information on the HBV vaccination coverage in Ger-
many. However, in adults (besides DEGS1) HBV vaccination in the GP was only covered by
two large surveys on self-reported vaccination status [32, 46]. Regarding populations at risk,
studies were more scarce, often smaller and more heterogenous regarding study population
and outcome measurement tool. Data from HCW was often self-reported and derived from
small sample sizes lacking robustness: except in two large studies on company doctors and
medical students, respectively, [22, 101] the study populations of studies in HCW comprised
less than 600 individuals. Studies in migrant/mobile populations varied in the target popula-
tion. Two studies were conducted among refugees from different countries and minor refugees
from Syria, respectively [44, 49, 61], while one large study was conducted in all patients with a
migration background recruited in primary care regardless of country of origin, direct- or
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indirect migration and length of stay in Germany [45]. The risk for VH of the latter may be
very different from the study populations of the other studies. Regarding MSM, most studies
were conducted in PLWH. In the only survey recruiting MSM without a known HIV-infec-
tion, the VH infection and vaccination status was self-reported [18]. For PLWH on the other
hand, one study in a non-MSM population recruited in HIV-care was identified [91]. People
in prison were only addressed by one study analysing the results of HCV routine testing of
prison inmates in Germany via questionnaires sent to the prison physicians [95]. For PWID,
we identified only two larger studies [28, 62], one of which included serology data in PWID
from several cities, while the other one only presented self-reported VH infection and vaccina-
tion status, resulting in a lower validity of the results [62].
Even if the overall evidence identified for HBV and HCV prevalence and HBV vaccination
coverage was considerable, evidence for both outcomes is found insufficient in PLWH, MSM
and HCV prevalence in mobile/migrant populations. Nonetheless, largest evidence gaps
regarding burden of disease were identified for HBV and HCV incidence and mortality. While
HCV incidence in the GP was calculated using the statutory health insurance data, for HBV
incidence in the GP, evidence was only gained from the blood donor surveillance. No evidence
was available in most populations at risk (HCW, migrant/mobile populations, people in prison
and PWID). Moreover, evidence was rare in PLWH and MSM. For HBV and HCV mortality
no evidence was available at all, except in clinical populations (PLWVH). Also for sequelae
and care, evidence was scarce. Proportions of persons with VH related acute liver failure,
hepatocellular carcinoma and liver transplantations were not covered by studies in the GP or
defined populations at risk. Additionally, for HBV no evidence was available for liver cirrhosis,
diagnosis and treatment in populations at risk. Evidence came mostly from PLWVH and clini-
cal populations with (severe) sequelae and both populations may represent a mixed population
of individuals at higher risk for VH than the GP. For HCV the evidence for treatment was
slightly better with rare evidence available for PLWH, MSM, people in prison and PWID but
not for HCW and migrant/mobile populations. However, the time frame of the literature
search only covered the beginning of the new HCV treatment era, so an increasing amount of
research regarding the proportion of HCV diagnosed and treated may be in the pipeline.
Moreover, unpublished data at the time of the search may currently be available. All outcomes
regarding sequelae and care were studied in PLWVH. Still, as mentioned above, parts of popu-
lations at risk for VH may not be sufficiently represented in clinical populations because of
lacking access to health care. Therefore the burden of sequelae and proportion treated may be
underestimated in these surveys.
One reason for the large evidence gaps regarding incidence studies might be the high costs
for cohort recruiting and follow-up. This also applies to studies on mortality, sequelae and
care. Here studies were mainly conducted in PLWVH, where recruitment is most convenient
and cost-effective. Notification data could provide some information about notification inci-
dence and time trends. Still, due to various reasons (e.g. underreporting and delay of notifica-
tion), notification data does not reflect the real incidence. In addition, secondary data (e.g.
from health insurance funds) could be a helpful and affordable source to gain more evidence
regarding VH incidence, mortality, sequelae and care in the GP.
Regarding population groups, the largest evidence gaps were found for research in sex
workers (not studied in any HBV- or HCV-related study), people in prison (only covered by a
single study regarding HCV prevalence and HCV treatment) and household contacts of
PLWVH. For studying populations at risk, using convenience samples may be necessary. Still,
outreach work and innovative sampling methods (e.g. respondent driven sampling) should be
applied to gain better access to some populations and to improve the representativeness of the
target population.
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In summary, generating evidence in all population groups is urgently needed regarding
HBV and HCV incidence and mortality. Moreover, in addition to updating the evidence on
prevalence from population-based surveys, focus should be targeted also on populations at
risk. So far not sufficiently included subpopulations should be included in the study design or
studies targeting these subpopulations must be carried out. This also applies to VH related
sequelae and proportion treated. Knowing the care cascade in selected populations at risk is
essential to evaluate the medical reachability of these groups, to plan targeted diagnostic and
treatment programmes.
With our review we assessed the existing body of evidence regarding several epidemiologi-
cal aspects of HBV, HCV and HDV in different population groups in Germany. The methods
used enabled us to cover multiple research questions in one search to obtain a broad overview
of all available evidence regarding VH epidemiology in Germany. We were also able to identify
important research gaps regarding relevant outcomes and to overview the consideration of dif-
ferent population groups. Analyzing the identified data in detail, the review can be used as a
reference to monitor the success of the national VH elimination strategy by comparing this
baseline with periodic updates. Moreover, the identified evidence gaps can help to designate
new targets for research in order to scale up operational research in fields with missing evi-
dence to complete the picture and to step further towards VH elimination.
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9. Santos-Hövener C., Schumann M., Schmich P., Gößwald A., A. R. Verbesserung der Informations-
grundlagen zur Gesundheit von Menschen mit Migrationshintergrund. Projektbeschreibung und erste
Erkenntnisse von IMIRA. Journal of Health Monitoring. 2019; 4(1):49–61. https://doi.org/10.25646/
5870
10. Bundesministerium für Gesundheit, Bundesministerium für wirtschaftliche Zusammenarbeit und
Entwicklung. Strategie zur Eindämmung von HIV, Hepatitis B und C und anderen sexuell übertragba-
ren Infektionen. Bis 2030—Bedarfsorientiert � Integriert � Sektorübergreifend. Berlin: 2016.
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22. Baars S. V89 Prävalenz von Hepatitis B und C bei medizinischen Fachangestellten. Arbeitsmedizin,
Sozialmedizin, Umweltmedizin. 2011; 46(3).
23. Baid-Agrawal S, Schindler R, Reinke P, Staedtler A, Rimpler S, Malik B, et al. Prevalence of occult
hepatitis C infection in chronic hemodialysis and kidney transplant patients. Journal of hepatology.
2014; 60(5):928–33. https://doi.org/10.1016/j.jhep.2014.01.012 PMID: 24447875
24. Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, et al. German cohort of HCV mono-
infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients.
AIDS Res Ther [Internet]. 2014 2014; 11:[16 p.]. https://doi.org/10.1186/1742-6405-11-16 PMID:
25006340
25. Bert F, Rindermann A, Abdelfattah MA, Stahmeyer JT, Rossol S. High prevalence of chronic hepatitis
B and C virus infection in a population of a German metropolitan area: A prospective survey including
10 215 patients of an interdisciplinary emergency unit. European Journal of Gastroenterology and
Hepatology. 2016; 28(11):1246–52. https://doi.org/10.1097/MEG.0000000000000702 PMID:
27439034
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metropolitan area in Germany: A retrospective study (2002–2008). Zeitschrift fur Gastroenterologie.
2009; 47(9):807–13. https://doi.org/10.1055/s-0028-1109058 PMID: 19750427
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